Literature DB >> 3530448

Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial.

J Keller, A Bartolucci, J T Carpenter, J Feagler.   

Abstract

Gallium nitrate was administered as a 700-mg/m2 iv bolus infusion over 15-30 minutes every 2 weeks to 138 patients with malignant lymphoproliferative diseases. Responses occurred in patients with well-differentiated lymphomas (five responses among eight patients), but the drug produced few responses in any other group of patients. Toxic effects were primarily gastrointestinal and reversible renal abnormalities and anemia. As a single agent, bolus gallium nitrate has little activity in lymphoproliferative diseases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530448

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

Review 1.  Medical applications and toxicities of gallium compounds.

Authors:  Christopher R Chitambar
Journal:  Int J Environ Res Public Health       Date:  2010-05-10       Impact factor: 3.390

2.  Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells.

Authors:  Meiying Yang; Christopher R Chitambar
Journal:  Free Radic Biol Med       Date:  2008-06-14       Impact factor: 7.376

Review 3.  Complexes of metals other than platinum as antitumour agents.

Authors:  P Köpf-Maier
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 4.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

5.  Gallium citrate, a new sensitizer of cells to hyperthermia.

Authors:  K Shinohara; N Kawakami; M Kugotani; H Nakano
Journal:  Jpn J Cancer Res       Date:  1988-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.